文献速递血栓与止血白血病MDS 与骨髓增殖性肿瘤

不依赖患者血小板计数的血小板聚集测定:一种流式细胞术方法

Measurement of platelet aggregation, independently of patient platelet count: a flow-cytometric approach.
PubMed 文献 · J Thromb Haemost · 2017-05-03

建立一种不依赖患者血小板计数的流式细胞术血小板聚集试验,并在19例健康个体和20例血小板计数≤50×10^9/L的急性髓系白血病或骨髓增生异常综合征患者中评估聚集与出血史的关系。患者血小板聚集较健康个体降低,聚集对出血倾向的阴性预测值为100%。

要点

  • 流式细胞术血小板聚集试验不依赖患者血小板计数,适用于血小板减少患者。
  • 血小板减少的血液肿瘤患者血小板聚集较健康个体降低。
  • 高血小板聚集对出血倾向的阴性预测值为100%。

核心结论

  • 所建立的血小板聚集试验适用于血小板减少患者,并提高了出血风险的识别。

研究设计与样本

  • 建立流式细胞术血小板聚集试验,先检测健康个体预孵育抗血小板药物样本和2例遗传性血小板疾病患者样本,再纳入19例健康个体和20例血小板计数≤50×10^9/L的急性髓系白血病或骨髓增生异常综合征患者。

主要发现

  • 血小板聚集试验的批内变异系数低,≤3%。
  • 血小板计数>10×10^9/L时,富血小板血浆与分离血小板的结果相似;否则需要分离血小板。
  • 血小板聚集百分比随抗血小板药物浓度增加而降低。
  • 患者血小板聚集较健康个体降低:TRAP刺激为42%(IQR 27-58)vs 66%(IQR 60-67);胶原相关肽刺激为41%(IQR 25-48)vs 70%(IQR 69-72);ADP刺激为44%(IQR 30-53)vs 65%(IQR 46-72)。
  • 患者刺激后血小板活化降低,并与血小板聚集相关(例如胶原相关肽刺激时r=0.78-0.81)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Essentials Platelet function may influence bleeding risk in thrombocytopenia, but useful tests are needed. A flow cytometric platelet aggregation test independent of the patient platelet count was made. Platelet aggregation was reduced in thrombocytopenic patients with hematological cancer. High platelet aggregation ruled out bleeding tendency in thrombocytopenic patients. SUMMARY: Background Methods for testing platelet aggregation in thrombocytopenia are lacking. Objective To establish a flow-cytometric test of in vitro platelet aggregation independently of the patient's platelet count, and examine the association of aggregation with a bleeding history in thrombocytopenic patients. Patients/methods We established a flow-cytometric assay of platelet aggregation, and measured samples from healthy individuals preincubated with antiplatelet drugs, and samples from two patients with inherited platelet disorders. Then, we included 19 healthy individuals and 20 patients with platelet counts of ≤ 50 × 109 L-1 , diagnosed with acute myeloid leukemia or myelodysplastic syndrome. We measured platelet aggregation and platelet activation by platelet surface expression of activated glycoprotein IIb-IIIa, P-selectin and CD63 after addition of agonists: collagen-related peptide, thrombin receptor-activating peptide (TRAP), and ADP. Results The platelet aggregation assay showed a low intraserial coefficient of variation of ≤ 3%. Similar results were obtained for platelet-rich plasma and isolated platelets at platelet counts of > 10 × 109 L-1 ; otherwise, platelet isolation was required. The platelet aggregation percentage decreased with increasing antiplatelet drug concentration. Platelet aggregation in patients was reduced as compared with healthy individuals: 42% (interquartile range [IQR] 27-58) versus 66% (IQR 60-67) for TRAP; 41% (IQR 25-48) versus 70% (IQR 69-72) for collagen-related peptide; and 44% (IQR 30-53) versus 65% (IQR 46-72) for ADP. Platelet activation after stimulation was reduced in patients and correlated with platelet aggregation (e.g. r = 0.78-0.81 when stimulated with collagen-related peptide). Platelet aggregation had a negative predictive value of 100% for a bleeding tendency among patients. Conclusion The established platelet aggregation assay was applicable for thrombocytopenic patients, and improved the identification of bleeding risk.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Vinholt PJ, Frederiksen H, Hvas AM, et al. Measurement of platelet aggregation, independently of patient platelet count: a flow-cytometric approach. J Thromb Haemost. 2017. PMID: 28296243. doi:10.1111/jth.13675

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。